Selective estrogen receptor modulators (SERMs) are a class of compounds that 
interact with estrogen receptors (ERs) and exert agonist or antagonist effects 
on ERs in a tissue-specific manner. Tamoxifen, a first generation SERM, is used 
for treatment of ER positive breast cancer. Raloxifene, a second generation 
SERM, was used to prevent postmenopausal osteoporosis. The third-generation SERM 
bazedoxifene (BZA) effectively prevents osteoporosis while preventing estrogenic 
stimulation of breast and uterus. Notably, BZA combined with conjugated 
estrogens (CE) is a new menopausal treatment. The menopausal state predisposes 
to metabolic syndrome and type 2 diabetes, and therefore the effects of SERMs on 
metabolic homeostasis are gaining attention. Here, we summarize knowledge of 
SERMs' impacts on metabolic, homeostasis, obesity and diabetes in rodent models 
and postmenopausal women.